Yoshino, Takayuki http://orcid.org/0000-0002-0489-4756
Shi, Qian http://orcid.org/0000-0002-4640-8832
Misumi, Toshihiro
Bando, Hideaki
Wakabayashi, Masashi
Raeisi, Morteza http://orcid.org/0000-0002-9999-4097
Andre, Thierry http://orcid.org/0000-0002-5103-7095
de Gramont, Aimery
Article History
First Online: 28 July 2023
Competing interests
: T.Y. reports honoraria from Bayer, Chugai, Merck Biopharma, MSD, Ono and Takeda; research funding from Taiho, Sumitomo Dainippon, Ono, Chugai, Amgen, Parexel International, MSD, Daiichi-Sankyo, Eisai, FALCO biosystems, Genomedia, Molecular Health, Nippon Boehringer Ingelheim, Pfizer, Roche Diagnostics, Sysmex and Sanofi. Q.S. reports a consulting and advisory role from Yiviva, Boehringer Ingelheim Pharmaceuticals, Regeneron Pharmaceuticals, Hoosier Cancer Research Network, Kronos Bio and Mirati Therapeutics; an honorarium and speaker role from Chugai Pharmaceutical Co. (directly to Q.S.); research funds from Celgene/BMS, Roche/Genentech, Janssen and Novartis (to Q.S.’s institution). T.M. reports honoraria from Chugai and AstraZeneca. H.B. reports a grant from Ono; honoraria from Taiho, Eli Lilly Japan and Ono. M.W. reports honoraria from Nihon Medi-Physics. T.A. reports attending advisory board meetings and receiving consulting fees from Aptitude Health, Astellas, Bristol Myers Squibb, Gilead, Gritstone Oncology, GamaMabs Pharma SA, GSK, Kaleido Oncology, Merck & Co., Seagen, Servier and Transgène; honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Bristol Myers Squibb, Gritstone Oncology, GSK, Merck & Co., Merck Serono, Pierre Fabre, Roche, Seagen and Servier; support for attending meetings and/or travel from Servier and Merck & Co.; and is President of the ARCAD Foundation. M.R. and A.G. have no competing interests to declare.